PsA: Rates of hospitalized serious infections lower with ustekinumab vs. other biologicsJune 4, 2021Psoriatic Arthritis
PsA: Upadacitinib shows consistent efficacy and safety in patients with inadequate response to biologicsJune 4, 2021Psoriatic Arthritis
PsA: No substantial change in body composition with ustekinumab treatmentJune 4, 2021Psoriatic Arthritis
Secukinumab, a comprehensive biologic treatment for management of concomitant PsA and psoriasisJune 4, 2021Psoriatic Arthritis
Is fecal microbiota transplantation beneficial in active peripheral PsA?June 4, 2021Psoriatic Arthritis
Rheumatology NewsNintedanib slows interstitial lung disease in RA patientsJune 4, 2021Rheumatoid Arthritis
Rheumatology NewsBEAT-LUPUS: Belimumab after rituximab delays severe flaresJune 3, 2021Lupus & Connective Tissue Diseases
Rheumatology NewsIntravenous immunoglobulin controls dermatomyositis in phase 3 trialJune 3, 2021Lupus & Connective Tissue Diseases
Rheumatology NewsFDA approves secukinumab in psoriasis patients age six and olderJune 2, 2021Pediatrics
